ShanghaiMay 12, 2026 /PRNewswire/ — Insilico Medicine (03696.HK), a generative AI-driven biotech company, today announced the signing of a strategic cooperation agreement with RiboBio (06938.HK), a globally positioned clinical-stage leader in small nucleic acid drug development. Building on their existing collaboration based on Insilico Medicine’s LifeStar 2 laboratory automation, intelligence, and scalability capabilities for experimental services, the two parties will further integrate Insilico Medicine’s proprietary end-to-end R&D capabilities from its Pharma.AI platform with RiboBio’s deep expertise in small nucleic acid drug development to comprehensively enhance the efficiency of small nucleic acid drug R&D.
Building on their existing collaboration based on Insilico Medicine’s LifeStar 2 laboratory automation, intelligence, and scalability capabilities for experimental services, the two parties will further integrate Insilico Medicine’s proprietary end-to-end R&D capabilities from its Pharma.AI platform with RiboBio’s deep expertise in small nucleic acid drug development to comprehensively enhance the efficiency of small nucleic acid drug R&D.
Dr. Gan Liming, Co-CEO and Global President of R&D at RiboBio, stated: “We are already in a new era of AI-guided clinical development. Insilico Medicine and RiboBio share a high degree of alignment in their innovative capabilities and mission visions within their respective fields. We are very pleased to reach a comprehensive strategic cooperation based on our previous seamless collaboration. Through years of technological accumulation and leveraging existing AI tools and methods, RiboBio has entered a rapid development phase of densely producing candidate drugs and efficiently advancing clinical trials. We believe that with the support of Insilico Medicine’s globally leading AI application systems, this will provide a powerful booster for our differentiated strategic development stage. We look forward to sparking innovative breakthroughs through close cooperation, further enhancing the efficiency and certainty of our drug development, and bringing AI-driven paradigm small nucleic acid therapies to benefit all of humanity as soon as possible.”
Dr. Ren Feng, Co-CEO and Chief Scientific Officer at Insilico Medicine, stated: “We are very pleased to sign a strategic cooperation agreement with RiboBio today. Insilico Medicine and RiboBio have maintained close communication and mutual trust. Notably, in 2025, RiboBio became the first partner for high-throughput experimental services on Insilico Medicine’s LifeStar 2 automated laboratory platform, highlighting the platform’s value in empowering the industry. With continuous innovations in AI algorithms, Insilico Medicine’s Pharma.AI platform has recently undergone several major upgrades. After in-depth discussions, both parties have reached a consensus on cooperation opportunities to leverage the Pharma.AI platform to empower multiple scenarios in small nucleic acid drug development. We will jointly promote relevant collaborations, end-to-end empower the development of small nucleic acid therapies, further broaden the boundaries of AI empowerment, and strive to meet unmet clinical needs.”
RiboBio (06938.HK) is a globally leading small nucleic acid drug development company. It has established a comprehensive small nucleic acid drug R&D platform covering the entire lifecycle, along with a globally integrated small nucleic acid drug development system. Its diversified pipeline in development covers major and chronic disease areas including cardiovascular, metabolic, kidney, and liver diseases. RiboBio’s proprietary RiboGalSTAR™ liver-targeting technology platform has advanced seven products to the clinical stage, with efficacy and safety well validated in clinical trials. Meanwhile, its RiboPepSTAR™ technology platform has made significant progress in extrahepatic areas such as the kidneys, heart, metabolism, and adipose tissue. RiboBio has entered into collaborations with multiple MNCs totaling over $6 billion, earning high international market recognition for its R&D platform and scientific capabilities.
Insilico Medicine is a globally leading AI-powered drug discovery technology company. Its proprietary end-to-end AI drug discovery platform, Pharma.AI, has enabled the identification of novel targets and the generation of a novel structure candidate drug, Rentosertib, which has completed initial proof-of-concept in a Phase IIa clinical trial. Benefiting from the continuous optimization of the Pharma.AI platform, Insilico Medicine has over 40 proprietary innovative pipelines and is consistently expanding into new modalities such as peptides, antibody-drug conjugates (ADCs), and proteolysis-targeting chimeras (PROTACs).
In the field of small nucleic acid drug development, AI technology has already played a significant role in areas such as target screening and identification, data modeling, and simulation. By evaluating the clinical effects of targets in large patient databases, it can predict clinical efficacy and safety, effectively improving the efficiency and certainty of clinical research. Based on this cooperation, Insilico Medicine’s AI technology empowerment system, covering the entire drug development process, will deeply synergize with RiboBio’s integrated small nucleic acid drug development platform, enhancing efficiency at various research stages and accelerating the development of innovative small nucleic acid drugs.
About Insilico Medicine
Insilico Medicine is a global pioneer biotechnology company dedicated to integrating artificial intelligence and automation technologies to accelerate drug discovery and drive innovation in life sciences, empowering people to live longer, healthier lives. On December 30, 2025, the company was listed on the Main Board of the Hong Kong Stock Exchange under the stock code 03696.HK.
Utilizing its proprietary Pharma.AI platform and advanced automated biology laboratories, Insilico Medicine is providing innovative drug solutions for unmet disease areas such as fibrosis, oncology, immunology, pain, obesity, and metabolic disorders. Additionally, Insilico Medicine continues to expand the application of Pharma.AI into diverse fields such as advanced materials, agriculture, nutritional products, and veterinary medicine. For more information, please visit www.insilico.com.
About RiboBio
Suzhou RiboBio Co., Ltd. is a global biopharmaceutical company focused on the development and commercialization of small interfering RNA (siRNA) drugs. Driven by its proprietary innovative small nucleic acid technology platform, the company has laid out a rich and differentiated product pipeline centered on major disease areas such as cardiovascular metabolism, liver, and kidney diseases. RiboBio is committed to providing revolutionary treatment options for patients worldwide through continuous innovation. On January 9, 2026, RiboBio was listed on the Main Board of the Hong Kong Stock Exchange under the stock code 06938.HK. For more information, please visit www.ribolia.com.